This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 May 2011

KemPharm Drug KP201 Proven to Relieve Pain

KemPharm announced positive results from a Phase 1 clinical trial of its most advanced opioid-based drug candidate, KP201, a novel hydrocodone prodrug for treating pain.

KemPharm, Inc. has reported positive results from a Phase I clinical trial of its opioid-based drug candidate, KP201.

 

The single dose, three-treatment, three-period, six-sequence and cross-over Phase I study included 24 healthy volunteers and showed the drug candidate reduced pain and improved pharmacokinetic profile.

 

The study also evaluated the serum concentrations of hydrocodone and intact KP201, as well as its safety and tolerability.

 

KemPharm Research vice-president Sven Guenther said: "The pharmacokinetic profile of KP201 indicates that the prodrug releases hydrocodone...and can deliver additional patient benefits, including reduced potential for abuse as w

Related News